Study on Belzutifan for Adolescents with Advanced Solid Tumors
Sponsor: Merck Sharp & Dohme LLC
ClinicalTrials ID:NCT07700758
This clinical trial is exploring the safety and tolerability of a new drug, belzutifan, in adolescents with certain advanced solid tumors that cannot be surgically removed or have spread to other parts of the body.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
Researchers are testing a new treatment called belzutifan for adolescents with specific types of advanced solid tumors. These include rare cancers like pheochromocytoma/paraganglioma (PPGL), a type of cancer in hormone-producing cells of the adrenal glands; wild type gastrointestinal stromal tumors (wtGIST), which are cancers in the digestive tract without certain gene changes; and tumors linked to Von Hippel-Lindau (VHL) disease, a genetic condition that can cause tumors. The study aims to see if belzutifan is safe and well-tolerated in these patients.
Eligibility Criteria
Inclusion Criteria
- Diagnosed with one of the following: advanced pheochromocytoma/paraganglioma, wild-type gastrointestinal stromal tumors, or localized tumors associated with Von Hippel-Lindau disease.
- Have measurable disease according to specific medical criteria.
Exclusion Criteria
- Oxygen levels below 92% at rest or need for supplemental oxygen.
- Significant heart disease or abnormal heart rhythms.
- History of HIV infection.
- Previous treatment with drugs similar to belzutifan.
- Recent organ or tissue transplant.
- Another active cancer needing treatment in the past 2 years.
- Active cancer spread to the brain or spinal fluid.
- Active infection needing treatment.
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| University of Iowa ( Site 5017) | 52242 | Iowa City | Iowa |
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.